Building a Biotech Powerhouse
Introduction: Established in 1978, Biocon Limited is Asia’s premier biotechnology company and India's largest biotechnology company by revenue. It is the only Asian company among the top 25 in global biopharma. Biocon is called as Poster child of Biotech in India. The Group, promoted by Ms. Kiran Mazumdar Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain extends the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human Insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM) 1. Biocon’s fully integrated business model spans the entire drug value chain, from preclinical discovery to clinical development and through to commercialization. Their businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth.
Biocon Press Release dated Oct 20, 2011. (http://www.biocon.com/docs/PR_201011_v1.pdf)
Corporate Structure of Biocon India:
Source: http://www.biocon.com/biocon_invrelation_org_structure.asp Syngene and Clinigene are the two main subsidiaries of Biocon India. Syngene is an internationally reputed contract research and manufacturing organization with multidisciplinary skills in chemistry and biology services. Clinigene International Limited is a fullservice Clinical Research Organization that partners with global pharmaceutical and biotechnology companies in their clinical development programs.1
During these successful 33 years of lifespan, the first 20 to 25 years, the company has not taken a single risk. Biocon has played safely in the past years. From last 5 years only, it has started taking risks. In 2004, Biocon and Vaccinex, Inc. have embarked on a broad, strategic partnership to discover and co-develop fully humanized antibodies focused on cancer, inflammation and autoimmune diseases.2 1
In 2007, Biocon signed a Memorandum of Understanding with Deakin University for cooperation in research and Biocon and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU. In 2009, Syngene International and Bristol-Myers Squibb (BMS) announced the opening of a fully dedicated research and development facility for BMS in Biocon Park, Bangalore. 1
Thus during last decade, Biocon has established itself up to the extent that, the best in the business Pfizer has also collaborated with Biocon. Pfizer and Biocon had $ 350M deal for the biosimilar insulin product and its rights of the sales. Biocon will receive $200 million from Pfizer under the deal that covers recombinant human insulin, Glargine, Aspart and Lispro. Biocon will be paid an additional $150 million on completion of regulatory approvals.2 BMS and Mylan also has the partnerships with Biocon.
2 novel drugs of biotech are in late stage clinical trials. Oral insulin and Anti CD6 are the two drugs. Oral insulin is the first in the world oral remedy for diabetes. Anti CD6 is entering into phase III clinical trials. Anti CD6 is the drug for Psoriasis which has affected to 1/3rd of the world population.3 1
Please join StudyMode to read the full document